TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Photocure ASA ( (PHCUF) ) has provided an announcement.
Photocure ASA presented findings from the BRAVO study at the Society of Urologic Oncology 2025 Annual Meeting, highlighting the cost-effectiveness of Blue Light Cystoscopy (BLC) in managing non-muscle-invasive bladder cancer (NMIBC). The study demonstrated that while BLC incurs higher initial costs compared to White Light Cystoscopy (WLC), it significantly reduces recurrence rates, leading to overall cost neutrality and superior clinical outcomes. These results support BLC’s use in high-risk NMIBC patient care, benefiting both patients and healthcare providers by improving treatment quality and managing costs effectively.
More about Photocure ASA
Photocure ASA, known as The Bladder Cancer Company, is a Norwegian firm specializing in innovative solutions for bladder cancer treatment. Their technology, which makes cancer cells glow bright pink, enhances tumor detection and management, improving patient outcomes. The company is publicly traded on the Oslo Stock Exchange and operates globally, with strategic partnerships in various countries.
YTD Price Performance: 6.94%
Average Trading Volume: 57,546
Current Market Cap: NOK1.8B
See more data about PHCUF stock on TipRanks’ Stock Analysis page.